CoTIL 01
Alternative Names: Autologous gene modified tumour infiltrating lymphocytes; CoTIL-01; CoTIL-01 - Immetacyte; Gene modified Tumour Infiltrating Lymphocytes; Tumour infiltrating lymphocyte therapy - Cellular TherapeuticsLatest Information Update: 28 Jan 2025
At a glance
- Originator Cellular Therapeutics
- Class Gene therapies; Immunotherapies; T lymphocyte cell therapies; Tumour infiltrating lymphocyte therapies
- Mechanism of Action Immunologic cytotoxicity; Lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Ovarian cancer
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for preclinical development in Ovarian-cancer in United Kingdom (Parenteral, Infusion)
- 23 Dec 2020 Cellular Therapeutics withdrew a phase I/IIa OVSTAR trial in Ovarian cancer in United Kingdom (Parenteral) due to sponsor's decision (NCT04389229)
- 01 Dec 2020 Preclinical trials in Ovarian cancer in United Kingdom (Parenteral) before December 2020 (NCT04389229)